RANTES In1.1C allele polymorphisms in 13 Chinese ethnic populations.
- Author:
Yuan QIAN
1
;
Hao SUN
;
Jia-you CHU
Author Information
- Publication Type:Journal Article
- MeSH: Alleles; Asian Continental Ancestry Group; genetics; Chemokine CCL5; genetics; Ethnic Groups; genetics; Genetic Predisposition to Disease; genetics; Genotype; Humans; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; genetics; Polymorphism, Single Nucleotide; genetics; Prevalence
- From: Chinese Medical Journal 2009;122(10):1143-1146
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDThe In1.1C single nucleotide polymorphism (SNP) allele results in reduced RANTES transcription, which is associated with increased frequency of HIV-1 infection, and rapid progression to AIDS among HIV-1-infected individuals. This study aimed to study the mutant frequency and polymorphism of RANTES in Chinese populations.
METHODSThe genotypes of RANTES In1.1C were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) with the digestion of restriction endonuclease Mbo II.
RESULTSOf the 617 individuals, 290 (47%) were carriers of the RANTES In1.1C allele, 52 of whom were homozygotes, whereas 238 were heterozygotes. The frequency of the RANTES In1.1C allele in those tested individuals was 0.2840. The frequencies of In1.1C allele varied from 0.07 - 0.27 in most of the populations in South-west China except for the two Lisu populations, while the frequencies of In1.1C spans from 0.35 to 0.45 in North-west China. The prevalence of the allele varied substantially between the South-west groups and North-west groups (chi(2) = 7.838, P = 0.006).
CONCLUSIONSThe prevalence of the RANTES In1.1C allele varies substantially between the South-west groups and North-west groups. There is no significant difference between the groups with different languages, which suggests that language relationship is not consistent with the genetic relationship. These results have important implications for the design, assessment, and implementation of HIV-1 vaccines.